drugset
drugset / Trial / NCT02264002

Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers

NCT02264002 ↗

Phase 1 Completed 119 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Pharmacodynamic effects on heart rate (HR) at rest and during exercise and on flicker fusion frequency (FFF), FFF method evaluation Safety, tolerability and pharmacokinetics of cilobradine

Timeline

Start
2003-02
Primary completion
2003-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Cilobradine Small molecule 0.25 mg Oral
Subject Cilobradine Small molecule 0.5 mg Oral
Subject Cilobradine Small molecule 1 mg Oral
Subject Cilobradine Small molecule 2 mg Oral
Subject Cilobradine Small molecule 4 mg Oral
Subject Cilobradine Small molecule 10 mg Oral
Subject Cilobradine Small molecule 14 mg Oral
Subject Cilobradine Small molecule 20 mg Oral
Comparator Metoprolol Other / unclassified 190 mg Oral

Indications

No indication recorded.